Cell4Cure AB
- Biotech or pharma, therapeutic R&D
Cell4Cure AB is a Swedish biotech company with breakthrough platform in immune tolerance therapies. Our innovation is autologous tolerogenic dendritic cells (tolDCs) – a precision approach to re-train the immune system and induce antigen specific tolerance.
Our platform brings a widely applicable solution for mitigating or eliminating costly barriers of Neutralizing Antibodies in Gene Therapy, Anti-Drug Antibodies (ADAs) in Checkpoint Inhibitors / Monoclonal Antibodies, autoimmune diseases and organ rejections. These types of immune responses are known to prevent patient recruitment, neutralize therapeutic efficacy or lead to adverse reactions. We intend to offer our platform solution to companies looking to overcome these costly therapeutic challenges where the real-world effect of immunogenicity a limitation.
Our lead product, ItolDC-028, is positioned to enter a Phase 1/2a clinical trial hemophilia A patients who developed these ADAs against factor VIII (FVIII).
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}